Analysis of rhinovirus capsid-binding compounds revealed two rhinovirus groups (A and B) with differential sensitivity, sequence divergence, and group B producing over twice as many clinical infections.
Rhinoviruses can be divided into two groups based on their sensitivity to capsid-binding antiviral compounds, which correlates with genetic divergence and clinical pathogenicity.
A variety of chemically different compounds inhibit the replication of several serotypes of rhinoviruses (common-cold viruses). We noticed that one of these antiviral compounds, WIN 51711, had an antiviral spectrum clearly distinctive from a consensus spectrum or other capsid-binding compounds, although all of them were shown to share the same binding site. A systematic evaluation of all known rhinovirus capsid-binding compounds against all serotyped rhinoviruses was therefore initiated. Multivariate analysis of the results revealed the existence of two groups of rhinoviruses, which we will call antiviral groups A and B. The differential sensitivity of members of these groups to antiviral compounds suggests the existence of a dimorphic binding site. The antiviral groups turned out to be a reflection of a divergence of rhinovirus serotypes on a much broader level. Similarities in antiviral spectra were highly correlated with sequence similarities, not only of amino acids lining the antiviral compound-binding-site, but also of amino acids of the whole VP1 protein. Furthermore, analysis of epidemiological data indicated that group B rhinoviruses produced more than twice as many clinical infections per serotype than group A rhinoviruses did. Rhinoviruses belonging to the minor receptor group were without exception all computed to lie in the same region of antiviral group B.
Andries et al. (Thu,) conducted a other in Rhinovirus infection. Rhinovirus capsid-binding compounds was evaluated on Antiviral sensitivity and sequence divergence. Analysis of rhinovirus capsid-binding compounds revealed two rhinovirus groups (A and B) with differential sensitivity, sequence divergence, and group B producing over twice as many clinical infections.